Incyte Corporation (BVMF:I1NC34)

Market Cap	105.68B
Revenue (ttm)	25.65B
Net Income (ttm)	6.33B
Shares Out	n/a
EPS (ttm)	31.46
PE Ratio	16.68
Forward PE	12.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	258
Average Volume	252
Open	279.72
Previous Close	n/a
Day's Range	279.16 - 280.84
52-Week Range	170.00 - 287.97
Beta	n/a
RSI	65.07
Earnings Date	Feb 3, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: I1NC34

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD